IPHA is expected to report earnings to fall 500.00% to -7 cents per share on September 15
Q2'22
Est.
$-0.08
Q2'23
Beat
by $0.16
The last earnings report on September 14 showed earnings per share of 1 cents, beating the estimate of -14 cents. With 1.70K shares outstanding, the current market capitalization sits at 188.72M.
a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment